Long term outcomes following anti-VEGF therapy for diabetic macular edema

References

• Varma R, Bressler NM, Doan QV, et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132(11):1334–1340.
   PubMed Web of Science ®Google Scholar
• Bhagat N, Grigorian RA, Tutela A, et al. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1–32.
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26(9):2653–2664.
   PubMed Web of Science ®Google Scholar
• ETDRS Study Research Group, Photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report number 1. Arch Ophthalmol. 1985;103(12):1796–1806.
   PubMedGoogle Scholar
• Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-Month data: report 3. Arch Ophtalmol. 2012;130(8):972–979.
   PubMed Web of Science ®Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–2022.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014;121(5):1045–1053.
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Li X, Koh A, et al. The REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology. 2015;122(7):1402–1415.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351–1359.
   PubMed Web of Science ®Google Scholar
• Bressler SB, Glassman AR, Almukhtar T, et al. Five-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema. Am J Ophthalmol. 2016;164:57–68.
   PubMed Web of Science ®Google Scholar
• Do DV, Nguyen QD, Khwaja AA, et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol. 2013;131(2):139–145.
   PubMed Web of Science ®Google Scholar
• Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da VINCI study of VEGF trap-eye in eyes with diabetic macular edema. Ophthalmology. 2012;119(8):1658–1665.
   PubMed Web of Science ®Google Scholar
• Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the vista and VIVID studies. Ophthalmology. 2016;123(11):2376–2385.
   PubMed Web of Science ®Google Scholar
• Waheed NK, Duker JS. OCT in the management of diabetic macular edema. Curr Ophthalmol Rep. 2013;1(3):128–133.
   Google Scholar
• Browning DJ, Stewart MW, Lee C. Diabetic macular edema: evidence-based management. Indian J Ophthalmol. 2018;66(12):1736–1750.
   PubMed Web of Science ®Google Scholar
• Baskin DE. Optical coherence tomography in diabetic macular edema. Curr Opin Ophthalmol. 2010;21(3):172–177.
   PubMed Web of Science ®Google Scholar
• Kumar V, Surve A, Kumawat D, et al. Ultra-wide field retinal imaging: a wider clinical perspective. Indian J Ophthalmol. 2021;69(4):824–835.
   PubMed Web of Science ®Google Scholar
• Ghasemi Falavarjani K, Tsui I, Sadda SR. Ultra-wide-field imaging in diabetic retinopathy. Vision Res. 2017;139:187–190.
   PubMed Web of Science ®Google Scholar
• Wecker T, Ehlken C, Bühler A, et al. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol. 2017;101(3):353–359.
   PubMed Web of Science ®Google Scholar
• Zirpel JJ, Pfister IB, Gerhardt C, et al. Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland. Graefe’s Arch Clin Exp Ophthalmol. 2021;259(12):3569–3578.
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Lasave AF, Wu L, et al. Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American collaborative retina study group. Br J Ophthalmol. 2016;100(12):1605–1610.
   PubMed Web of Science ®Google Scholar
• Sun JK, wen WP, Taylor S, et al. Durability of diabetic retinopathy improvement with as-needed ranibizumab: open-label extension of RIDE and RISE studies. Ophthalmology. 2019;126(5):712–720.
   PubMed Web of Science ®Google Scholar
• Borrelli E, Grosso D, Barresi C, et al. Long-term visual outcomes and morphologic biomarkers of vision loss in eyes with diabetic macular edema treated with anti-VEGF therapy. Am J Ophthalmol. 2022;235:80–89.
   PubMed Web of Science ®Google Scholar
• Kessler LJ, Auffarth GU, Bagautdinov D, et al. Ellipsoid zone integrity and visual acuity changes during diabetic macular edema therapy: a longitudinal study. J Diabetes Res. 2021;2021:1–10.
   Google Scholar
• Maggio E, Sartore M, Attanasio M, et al. Anti–vascular endothelial growth factor treatment for diabetic macular edema in a real-world clinical setting. Am J Ophthalmol. 2018;195:209–222.
   PubMed Web of Science ®Google Scholar
• Maguire MG, Liu D, Glassman AR, et al. Visual field changes over 5 years in patients treated with panretinal photocoagulation or ranibizumab for proliferative diabetic retinopathy. JAMA Ophthalmol. 2022;138(3):285–293.
   Web of Science ®Google Scholar
• Hutton DW, Stein JD, Glassman AR, et al. Five-year cost-effectiveness of intravitreous ranibizumab therapy vs panretinal photocoagulation for treating proliferative diabetic retinopathy: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2019;137(12):1424–1432.
   PubMed Web of Science ®Google Scholar
• Boyer DS, Nguyen QD, Brown DM, et al. Outcomes with as-needed ranibizumab after initial monthly therapy: long-term outcomes of the phase III RIDE and RISE trials. Ophthalmology. 2015;122(12):2504–2513.
   PubMed Web of Science ®Google Scholar
• Gross JG, Glassman AR, Liu D, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2018;136(10):1138–1148.
   PubMed Web of Science ®Google Scholar
• Bressler SB, Odia I, Glassman AR, et al. Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab DRCR.NET protocol I 5-year report. Retina. 2018;38(10):1896–1904.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Elman MJ, Regillo CD, et al. Predictors of diabetic macular edema treatment frequency with ranibizumab during the open-label extension of the RIDE and RISE trials. Ophthalmology. 2016;123(8):1716–1721.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Ou WC, Khurana RN, et al. Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study. Br J Ophthalmol. 2018;102(5):631–636.
   PubMed Web of Science ®Google Scholar
• Glassman AR, Wells JA, Josic K, et al. Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T extension study). Ophthalmology. 2020;127(9):1201–1210.
   PubMed Web of Science ®Google Scholar
• Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt vs. deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122(2):375–381.
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Hussain RM, Taraborelli D, et al. Longer-term anti-vegf therapy outcomes in neovascular age-related macular degeneration, diabetic macular edema, and vein occlusion-related macular edema clinical outcomes in 130 247 eyes. Ophthalmol Retina. 2022;6(9):796–806.
   PubMedGoogle Scholar
• Biechl AC, Bhandari S, Nguyen V, et al. Changes in real-world treatment patterns for diabetic macular oedema from 2009 to 2019 and 5-year outcomes: data from the fight retinal blindness! Registry. Clin Exp Ophthalmol. 2020;48(6):802–812.
   PubMed Web of Science ®Google Scholar
• Weingessel B, Miháltz K, Gleiss A, et al. Treatment of diabetic macular edema with intravitreal antivascular endothelial growth factor and prompt versus deferred focal laser during long-term follow-up and identification of prognostic retinal markers. J. Ophthal. 2018; 2018: 1–11.
   Web of Science ®Google Scholar
• Maguire MG, Liu D, Bressler SB, et al. Lapses in care among patients assigned to ranibizumab for proliferative diabetic retinopathy a post hoc analysis of a randomized clinical trial supplemental content and journal club slides. JAMA Ophthalmol. 2021;139. 1266–1273.
   PubMed Web of Science ®Google Scholar
• Khoshnood B, Mesbah M, Jeanbat V, et al. Transforming scales of measurement of visual acuity at the group level. Ophthalmic Physiol Optics. 2010;30(6):816–823.
   PubMed Web of Science ®Google Scholar
• Rosenthal Robert. Meta-analytic procedures for social research. In: Brickman L, Rog D, editors. Applied social research methods series. Vol. 6. Newbury (CA): SAGE Publications, Inc; 1993.
   Google Scholar
• Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–1077.
   PubMed Web of Science ®Google Scholar
• Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20):2137–2146. Erratum in: JAMA. 315(9), 944 (2016). Erratum in: JAMA. 321(10), 1008 (2019).
   PubMed Web of Science ®Google Scholar
• Romero-Aroca P, de La Riva-Fernandez S, Valls-Mateu A, et al. Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up. BMC Ophthalmol. 2016;16(1). doi:10.1186/s12886-016-0318-x.
   PubMedGoogle Scholar
• Gabrielle PH, Nguyen V, Bhandari S, et al. Initial observation or treatment for diabetic macular oedema with good visual acuity: two-year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry. Acta Ophthalmol. 2022;100(3):285–294.
   PubMed Web of Science ®Google Scholar
• Virgili G, Parravano M, Evans JR, et al.Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2017;6(6). Published online 2017 Jun 22. [Accessed 2022 Aug 31]
   PubMedGoogle Scholar
• Brown DM, Emanuelli A, Bandello F, et al. KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema. Am J Ophthalmol. 2022;238:157–172.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326): 741–755.
   PubMed Web of Science ®Google Scholar
• Roche Doing now what patients need next [Internet]. cited 2022 Aug 31. Available from: https://www.roche.com/media/releases/med-cor-2021-10-22b.
   Google Scholar
• Urbančič M, Topčić IG. Dexamethasone implant in the management of diabetic macular edema from clinician’s perspective. Clin Ophthalmol. 2019;13:821–828.
   PubMed Web of Science ®Google Scholar
• Madjedi K, Pereira A, Ballios BG, et al. Switching between anti-VEGF agents in the management of refractory diabetic macular edema: a systematic review. Surv Ophthalmol. 2022;67(5):1364–1372.
   PubMed Web of Science ®Google Scholar